Table 3:

Logistic Regression of MOUD as first-choice treatment (versus non-medication treatment), by race/ethnicity

	White		Black		Latino/a
	OR (95% CI)	Adjusted p-value†	OR (95% CI)	Adjusted p-value†	OR (95% CI)	Adjusted p-value†
Demographics
Gender (ref=woman)	0.59 (0.33 – 1.05)	0.211	0.89 (0.54 – 1.46)	0.788	0.75 (0.43 – 1.31)	0.668
Age	1.02 (0.86 – 1.20)	0.950	0.96 (0.84 – 1.1)	0.742	1.01 (0.86 – 1.19)	0.918
Income	1.25 (0.91 – 1.72)	0.383	1.34 (1.04 – 1.76)	0.153	1.22 (0.89 – 1.67)	0.595
Treatment Knowledge (ref = none at all + a little knowledge)
MOUD treatment	1.13 (0.48 – 2.72)	0.950	0.80 (0.44 – 1.43)	0.703	1.06 (0.56 – 2.01)	0.918
Non-medication treatment	2.03 (1.03 – 4.17)	0.211	2.41 (1.34 – 4.34)	0.035	1.30 (0.68 – 2.50)	0.671
Treatment Access (ref = not sure + have difficulty in access treatment)
Methadone	0.71 (0.26 – 1.91)	0.783	1.08 (0.53 – 2.2)	0.925	2.08 (0.82 – 5.25)	0.494
Buprenorphine	3.87 (1.04 – 15.02)	0.211	1.73 (0.71 – 4.19)	0.499	1.26 (0.44 – 3.64)	0.903
Naltrexone	0.96 (0.26 – 3.29)	0.950	0.96 (0.38 – 2.37)	0.929	0.51 (0.2 – 1.22)	0.494
Non-medication treatment	0.94 (0.44 – 2.04)	0.950	0.74 (0.4 – 1.35)	0.593	1.31 (0.7 – 2.47)	0.671
Opioid use
Self-reported OUD (lifetime)	1.96 (0.52 – 12.8)	0.710	2.15 (0.72 – 9.28)	0.499	1.21 (0.43 – 4.32)	0.903

Note: OUD, Opioid Use Disorder; OR, Odds Ratio; CI, Confidence Interval

^†p-values were adjusted to control FDR < 0.05.